New anticancer agents: Hormones made within the heart

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2515-2522

  Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; Metastasis; Natriuretic peptides; Review

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; HORMONE; HORMONE PRECURSOR; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NUCLEAR MATRIX PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL DEATH; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; HUMANS; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PROTEIN PRECURSORS;

EID: 84865691151     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Brenner BM, Ballermann BJ, Gunning ME and Ziedel ML: Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70: 665-699, 1990. (Pubitemid 20196047)
2. Gardner DG, Kovacic-Milivojevic BK and Garmai M: Molecular biology of the natriuretic peptides. In: Atrial Natriuretic Peptides. Vesely DL (ed.). Trivandrum, India: Research Signpost pp. 15-38, 1977.
3. Vesely DL: Natriuretic Hormones. In: Seldin and Geibisch's The Kidney: Physiology and Pathophysiology, 4th Edition. Alpern RJ and Hebert SC (eds.). San Diego, CA: Elsevier, Academic Press, pp. 947-977, 2007.
4. Martin DR, Pevahouse JB, Trigg DJ, Vesely DL and Buerkert JE: Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliuretic. Am J Physiol 258: F1401-F1408, 1990. (Pubitemid 20185280)
5. Gunning ME, Brady HR, Otuechere G, Brenner BM and Ziedel ML: Atrial natriuretic peptide (31-67) inhibits Na transport in rabbit inner medullary collecting duct cells: role of prostaglandin E2. J Clin Invest 89: 1411-1417, 1992.
6. Benjamin B and Peterson TV: Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 269: R1351-R1355, 1995.
7. Zeidel ML: Regulation of collecting duct Na+ reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 22: 121-124, 1995.
8. Villarreal D, Reams GP, Taraben A and Freeman RH: Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 221: 166-170, 1999.
9. Dietz JR, Scott DY, Landon CS and Nazian SJ: Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 280: R1510-R1517, 2001.
10. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr., McCormick MT, Rodriguez-Paz G and Schocken DD: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 90: 1129-1140, 1994. (Pubitemid 24284433)
11. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr., McCormick MT, Rodriguez-Paz G and Schocken DD: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 78: 1128-1134, 1994. (Pubitemid 24143035)
12. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G and Schocken DD: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 98: 323-329, 1998. (Pubitemid 28348054)
13. Vesely DL: Atrial Natriuretic Hormones. Englewood Cliffs, NJ: Prentice Hall, pp. 1-256, 1992.
14. Vesely DL: Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that up-regulate its expression. IUBMB Life 53: 153-159, 2002.
15. Winters CJ, Sallman AL, Baker BJ, Meadows JJ, Rice DM and Vesely DL: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 80: 438-449, 1989. (Pubitemid 19231377)
16. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL and Epstein M: Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 192: 230-235, 1989. (Pubitemid 20051475)
17. Hunter EFM, Kelly PA, Prowse C, Woods FJ and Lowry PJ: Analysis of peptides derived from pro-atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 58: 205-216, 1998. (Pubitemid 28308206)
18. De Palo EF, Woloszczuk W, Meneghetti M, DePalo CB, Nielsen HB and Secher NH: Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 46: 843-847, 2000. (Pubitemid 30397449)
19. Franz M, Woloszczuk W and Horl WH: N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 58: 374-378, 2000.
20. Franz M, Woloszczuk W and Horl WH: Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney disease. Kidney Int 59: 1928-1934, 2001. (Pubitemid 32336809)
21. Vesely BA, McAfee Q, Gower WR Jr. and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003. (Pubitemid 37421599)
22. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SR, Gower WR Jr. and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005. (Pubitemid 40187955)
23. Vesely BA, Alli AA, Song S, Gower WR Jr., Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005. (Pubitemid 41640906)
24. Gower WR Jr., Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′,5′-cyclic monophosphate. Int J Gastrointestinal Cancer 36: 77-87, 2006.
25. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 36: 810-819, 2006. (Pubitemid 44569970)
26. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy 5: 97-104, 2007.
27. Vesely BA, Alli A, Song S, Sanchez-Ramos J, Fitz SR, Gower WR Jr. and Vesely DL: Primary malignant tumors of the heart: Four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology 105: 226-233, 2006. (Pubitemid 43725777)
28. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci 334: 342-349, 2007. (Pubitemid 351339267)
29. Eichelbaum EJ, Vesely BA, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones decrease up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine 30: 325-332, 2006. (Pubitemid 47010969)
30. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr. and Vesely DL: Four cardiac hormones eliminate four-fold more human glioblastoma cells than green mamba snake peptide. Cancer Lett 254: 94-101, 2007. (Pubitemid 47058809)
31. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Gower WR Jr. and Vesely DL: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 35: 388-398, 2005. (Pubitemid 40826838)
32. Vesely BA, Fitz SR, Gower WR Jr. and Vesely DL: Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 233: 226-231, 2006. (Pubitemid 43327377)
33. Pitchumoni CS: Pancreatic Disease. In: Internal Medicine. Stein JH (ed.). St. Louis, MO: Mosby pp. 2233-2247, 1998.
34. Wolff RA, Abbruzzese JL and Evans DB: Neoplasms of the exocrine pancreas. In: Cancer Medicine, Holland JF, Frei E III (eds.). London, UK: BC Decker Inc. pp. 1436-1464, 2000.
35. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL and Gower WR Jr.: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21: 445-452, 2007. (Pubitemid 46901402)
36. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. and Vesely DL: Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 38: 562-570, 2008. (Pubitemid 352019135)
37. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alii AA and Gower WR Jr.: Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 21: 973-978, 2007. (Pubitemid 350286323)
38. Scholl FA, Dumesic PA and Khavari PA: Effects of active MEK 1 expression in vivo. Cancer Lett 230: 1-5, 2005. (Pubitemid 41506954)
39. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelle AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
40. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the Ras mitogen-activated protein kinase pathway. Clin Can Res 14: 3651-3656, 2008.
41. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT and Steelman LS: Targeting the RAF/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9: 614-630, 2008. (Pubitemid 351777165)
42. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit RAS in human prostate cancer cells. Anticancer Res 29: 971-975, 2009.
43. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit RAS in human prostate cancer cells. Anticancer Res 29: 1889-1893, 2009.
44. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Epidermal growth factor's activation of RAS is inhibited by four cardiac hormones. Eur J Clin Invest 40: 408-413, 2010.
45. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 1387-1392, 2007. (Pubitemid 46807213)
46. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK1/2 activation in human prostate cancer cells. Anticancer Res 27: 3813-3818, 2007.
47. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006. (Pubitemid 44701488)
48. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK1/2 in prostate cancer cells. Anticancer Res 26: 4143-4148, 2006. (Pubitemid 46031483)
49. Kyriakas JM, Banerjee P, Nikolakaki E, Dai TA, Rubie EA, Ahmad MF, Avruch J and Woodge H Jr.: The stress-activated proteinkinase subfamily of c-Jun kinases. Nature 369: 156-160, 1994. (Pubitemid 24153440)
50. Heasley LE and Han SY: JNK regulation of oncogenesis. Mol Cells 21: 167-173, 2006.
51. Derijard R, Hibi M, Wu IH, Barrett T, Su B, Deng TL, Karin M and Davis RJ: Jnk1 - a protein-kinase stimulated by UV-light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037, 1994. (Pubitemid 24106383)
52. Rosette C and Karin M: Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274: 1194-1197, 1996. (Pubitemid 26389285)
53. Bost F, Dean N, McKay R and Mercola D: Activation of the Jun kinase/stress-activated protein kinase pathway is required for EGF-autocrine stimulated growth of human A549 lung carcinoma cells. J Biol Chem 272: 33422-33429, 1997. (Pubitemid 28023696)
54. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL and Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by RAF-1 and MEKK. Science 266: 1719-1723, 1994.
55. Juneja J, Cushman I and Casey PJ: G12 Signaling through c-Jun NH2-terminal kinase promotes breast cancer cell invasion. PLoS One 6(11): e26085 2011.
56. Xia L, Dickens M, Raingeaud J, David RJ and Greenberg ME: Opposing effects of ERK and JNK-p 38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
57. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS, Depatie C and Mercola D: c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 9: 391-401, 2003. (Pubitemid 36109757)
58. Bost F, Potapova O, Liu C, Zhang YM, Charbono W, Dean N, McKay R and Mercola D: High frequency regression of established human prostate carcinoma PC3 xenografts by systemic treatment with antisense Jun kinase. Prostate 38: 320-321, 1999.
59. Bost F, McKay R, Bost M, Potapova O, Dean NM and Mercola D. Jun kinase-2 isoform is preferentially required for epidermal growth factor-induced proliferation of human A549 lung carcinoma. Mol Cell Biol 19: 1938-1949, 1999. (Pubitemid 29098252)
60. Lane ML, Santana O, Frost CD, Nguyen J, Guerrero J, Skelton WP IV, Skelton M and Vesely DL: Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides. Anticancer Res 32: 721-726, 2012.
61. Niles AL, Moravec RA, Hesselberth E, Scurria MA, Daily WJ and Riss TL: A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal Biochem 366: 197-206, 2007. (Pubitemid 46898209)
62. Pi GE, Skelton WP IV and Vesely DL: Four cardiac hormones cause cytotoxicity of human cancer cells but not of healthy cells. Cancer Therapy 8: 44-50, 2011.
63. Hancock R and Boulikas T: Functional organization in the nucleus. Int Rev Cytol 79: 165-214, 1982. (Pubitemid 13178586)
64. Bouteille M, Bouvier D and Seve AP. Heterogeneity and territorial organization of the nuclear matrix and related structures. Int Rev Cytol 83: 135-182, 1983. (Pubitemid 14237806)
65. Berrios M, Osheroff N and Fisher PA: In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophilia nuclear matrix fraction. Proc Natl Acad Sci USA 82: 4142-4146, 1985. (Pubitemid 15053599)
66. Zeitlin S, Parent A, Silverstein S and Efstratiadis J: Pre mRNA splicing and the nuclear matrix. Mol Cell Biol 7: 111-120, 1987. (Pubitemid 17230390)
67. Skelton WP IV, Pi GE and Vesely DL: Four cardiac hormones cause death of human cancer cells but not of healthy cells. Anticancer Res 31: 395-402, 2012.